Oncology Clinical Pathways Spotlight
This week in health care trends, our spotlight on clinical pathways in oncology includes updates about payment reform, 30 young up-and-coming healthcare innovators, and the ongoing debate over immunotherapy.
The four articles below are from our dedicated Clinical Pathways e-magazine. We’re constantly adding valuable content to this updateable magazine, so make sure to check our e-magazine frequently for new intelligence. You can follow us on Flipboard or Twitter, or just watch for the links to this and our other magazines in our regular weekly BioBlog emails. (Don’t get our emails yet? Subscribe here!)
As more high-cost immunotherapies to treat cancer are approved by the FDA, the debate over their role in cancer treatment — and their effect on the cost of treatment — continues.
This Forbes spotlight introduces 30 young up-and-coming entrepreneurs who are “finally dragging our medical system kicking and screaming into the digital age.” Included are Flatiron Health co-founder Nat Turner, MIT assistant professor Nikhil Agarwal, and Transplants Without Donors co-founder Eleni Antoniadou, along with 27 other rising stars of healthcare innovation.
Dr. Alan Weil shares in this HealthAffairs article his five reasons for opposing payment reform. He argues that payment reform stems from a flawed premise, that it would be a “marginal change”, and that there is insufficient evidence to demonstrate that payment reform would help create the necessary changes to the system. In a follow-up post, Dr. Weil also shares five things payment reform would need in order to be more effective and successful.
The Harvard Business Review makes an argument that “it is time to optimize the integrated-care model and accelerate its adoption more broadly and deeply across the American health care system.” Suggested action steps include aligning payment with integrated care, improving processes, creating universal electronic health records (EHRs), and reducing dependence on specialty care.